Victory Capital Management Inc. Has $2.03 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Victory Capital Management Inc. lessened its stake in Repligen Co. (NASDAQ:RGEN) by 29.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,624 shares of the biotechnology company’s stock after selling 5,564 shares during the quarter. Victory Capital Management Inc.’s holdings in Repligen were worth $2,028,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of RGEN. Andra AP fonden acquired a new stake in Repligen during the second quarter worth approximately $25,000. Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. UMB Bank n.a. boosted its holdings in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. grew its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter valued at approximately $33,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $142.58 on Monday. The firm has a market capitalization of $7.99 billion, a PE ratio of -385.34, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a 50 day moving average price of $140.26 and a 200-day moving average price of $143.27. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business earned $0.23 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities research analysts expect that Repligen Co. will post 1.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.